Lead Product(s) : Ladarixin
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dompé Presents Phase II Clinical Trial Results for Ladarixin in New-Onset Type 1 Diabetes
Details : Results from Phase 2 trial demonstrate that ladarixin, a novel small molecule that inhibits the biological activity of IL-8, has potential activity in the preservation of β-cell function in new-onset type 1 diabetes (T1D).
Product Name : MEX0114
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 15, 2020
Lead Product(s) : Ladarixin
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
